REFERENCES
1. The International Non-Hodgkin’s Lymphoma Prognostic Factors Project.
A predictive model for aggressive Non-Hodgkin’s lymphoma.
1993;329(14):987-94.
2. International Agency for Research on Cancer. World Cancer Report
2014. Book Chapter 5.13. Stewart BW, Wild CP. Haematopoietic and
Lymphoid Malignancy.IAfRoC. 2014; 482-486.
3. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et
al. The revised International Prognostic Index (R-IPI) is a better
predictor of outcome than the standard IPI for patients with diffuse
large B-cell lymphoma treated with R-CHOP. 2007;109(5):1857-61.
4. Greb A, Bohlius J, Schiefer D, Schwarzer G, Schulz H, Engert A.
High-dose chemotherapy with autologous stem cell transplantation in the
first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.
Cochrane Database of Systematic Reviews. 2008(1).
5. Stiff PJ, Unger JM, Cook JR, Constine LS, Couban S, Stewart DA, et
al. Autologous transplantation as consolidation for aggressive
non-Hodgkin’s lymphoma. N Engl J Med. 2013;369(18):1681-90.
6. Nademanee A, Molina A, O’Donnell MR, Dagis A, Snyder DS, Parker P, et
al. Results of high-dose therapy and autologous bone marrow/stem cell
transplantation during remission in poor-risk intermediate- and
high-grade lymphoma: international index high and high-intermediate risk
group. Blood. 1997;90(10):3844-52.
7. Kewalramani T, Zelenetz AD, Hedrick EE, Donnelly GB, Hunte S,
Priovolos AC, et al. High-dose chemoradiotherapy and autologous stem
cell transplantation for patients with primary refractory aggressive
non-Hodgkin lymphoma: an intention-to-treat analysis.
2000;96(7):2399-404.
8. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van Der Lelie H, Bron
D, et al. Autologous bone marrow transplantation as compared with
salvage chemotherapy in relapses of chemotherapy-sensitive Non-Hodgkin’s
lymphoma. 1995;333(23):1540-5.
9. National Comprehensive Cancer Network. NCCN Clinical practice
guidelines in oncology: Non Hodgkin’s lymphomas (2016). [online]
Version 2:Available from:
https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.
[Accessed September 14, 2018].
10. Vose JM, Zhang M-J, Rowlings PA, Lazarus HM, Bolwell BJ, Freytes CO,
et al. Autologous transplantation for diffuse aggressive Non-Hodgkin’s
lymphoma in patients never achieving remission: a report from the
autologous blood and marrow transplant registry. 2001;19(2):406-13.
11. Narendranath Epperla, Neto AEH, Costa LJ. Recent Survival Trends in
Diffuse Large B-Cell Lymphoma (DLBCL)-Did We Make Any Progress Beyond
Rituximab? Blood. 2018;132:4828.
12. Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin
J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results
from the international SCHOLAR-1 study. Blood. 2017;130(16):1800-8.
13. Miyoshi H, Ohshima K. Epidemiology of malignant lymphoma and recent
progress in research on adult T-cell leukemia/lymphoma in Japan. Int J
Hematol. 2018;107(4):420-7.
14. Intragumtornchai T, Bunworasate U, Wudhikarn K, Lekhakula A,
Julamanee J, Chansung K, et al. Non-Hodgkin lymphoma in South East Asia:
An analysis of the histopathology, clinical features, and survival from
Thailand. Hematol Oncol. 2018;36(1):28-36.
15. Intragumtornchai T, Wannakrairoj P, Chaimongkol B, Bhoopat L,
Lekhakula A, Thamprasit T, et al. Non‐Hodgkin’s lymphomas in Thailand: A
retrospective pathologic and clinical analysis of 1391 cases. Cancer.
1996;78(8):1813-9.
16. Mozaheb Z. Epidemiology of Lymphoid Malignancy in Asia. Epidemiology
Insights. 2012.
17. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et
al. Comparison of a standard regimen (CHOP) with three intensive
chemotherapy regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med.
1993;328(14):1002-6.
18. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R, et
al. Comparison of a second-generation combination chemotherapeutic
regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse
non-Hodgkin’s lymphoma. N Engl J Med. 1992;327(19):1342-9.
19. Nakaya A, Fujita S, Satake A, Nakanishi T, Azuma Y, Tsubokura Y, et
al. Upfront high-dose chemotherapy combined with autologous stem cell
transplantation: Potential survival benefit for patients with high-risk
diffuse large B-cell lymphoma. Oncology letters. 2017;14(3):3803-8.
20. Inano S, Iwasaki M, Iwamoto Y, Sueki Y, Fukunaga A, Yanagita S, et
al. Impact of high-dose chemotherapy and autologous transplantation as
first-line therapy on the survival of high-risk diffuse large B cell
lymphoma patients: a single-center study in Japan. Int J Hematol.
2014;99(2):162-8.
21. Japanese Society of Hematology. Clinical practice guideline.
[online] Available from:
http://www.jshem.or.jp/gui-hemali/table.html. [Accessed 14
September, 2018].
22. Vitolo U, Chiappella A, Brusamolino E, Angelucci E, Balzarotti M,
Carella A, et al. A randomized multicentre phase III study for first
line treatment of young patients with high risk (AAIPI 2-3) diffuse
large B-cell lymphoma (DLBCL): Rituximab (R) plus dose-dense
chemotherapy CHOP14/MegaCHOP14 with or without intensified high-dose
chemotherapy (HDC) and autologous stem cell transplantation (ASCT).
Results of DLCL04 trial of Italian Iymphoma Foundation (FIL)2011. 106-
p.
23. Reddy NM, Oluwole O, Greer JP, Engelhardt BG, Jagasia MH, Savani BN.
Outcomes of autologous or allogeneic stem cell transplantation for
non-Hodgkin lymphoma. Exp Hematol. 2014;42(1):39-45.
24. Dowling AJ, Prince HM, Wirth A, Wolf M, Januszewicz EH, Juneja S, et
al. High-dose therapy and autologous transplantation for lymphoma: The
Peter MacCallum Cancer Institute experience. Internal Medicine Journal.
2001;31(5):279-89.
25. Shi Y. Current status and progress of lymphoma management in China.
Int J Hematol. 2018;107(4):405-12.
26. Nair R, Arora N, Mallath MK. Epidemiology of Non-Hodgkin’s Lymphoma
in India. Oncology. 2016;91 Suppl 1:18-25.
27. Lim RB, Loy EY, Lim GH, Zheng H, Chow KY, Lim ST. Gender and ethnic
differences in incidence and survival of lymphoid neoplasm subtypes in
an Asian population: Secular trends of a population-based cancer
registry from 1998 to 2012. Int J Cancer. 2015;137(11):2674-87.
28. Ziepert M, Hasenclever D, Kuhnt E, Glass B, Schmitz N, Pfreundschuh
M, et al. Standard International prognostic index remains a valid
predictor of outcome for patients with aggressive CD20+ B-cell lymphoma
in the rituximab era. J Clin Oncol. 2010;28(14):2373-80.
29. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C, et al.
The International Prognostic Index correlates to survival in patients
with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma
Group. Blood. 1998;92(10):3562-8.
30. Project TN-HsLC. Effect of age on the characteristics and clinical
behavior of non-Hodgkin’s lymphoma patients. Annals of Oncology.
1997;8(10):973-8.
31. Fanin RS, A.; Elvira, C.; Zaja, F.; Stocchi, R.; Geromin, A.; Cerno,
M.; Patriarca, F.; Canelles, M.; Damiani, D.; Baccarani, M. . A
retrospective analysis of 144 patients with aggressive non-Hodgkin’s
lymphoma: impact of autologous stem cell transplantation in first
remission on outcome Haematologica. 2000;85(9):943-51.
32. Vivas YAV, Hungria VTM, Costa LJM, Dos Santos KB, Chaoubah A,
Bustamante-Teixeira MT, et al. Up-front autologous hematopoietic stem
cell transplantation (AHSCT) from a single Brazilian center. Bone Marrow
Transplant. 2019.
33. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse
large B-cell lymphoma identified by gene expression profiling. Nature.
2000 2000/02;403:503-11.
34. Rosenwald A, Wright G, Chan WC, et al. The Use of Molecular
Profiling to Predict Survival after Chemotherapy for Diffuse
Large-B-Cell Lymphoma. The New England journal of medicine. 2002
2002/06/20;346:1937-47.
35. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma
outcome prediction by gene-expression profiling and supervised machine
learning. Nature medicine. 2002 2002/01;8:68-74.
36. Wright G, Tan B, Rosenwald A, et al. A gene expression-based method
to diagnose clinically distinct subgroups of diffuse large B cell
lymphoma. Proc Natl Acad Sci U S A. 2003 2003/08/04;100:9991-6.